Dicarboxylic Acid Compound for Hyperphosphatemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic drugs for hyperphosphatemia, such as phosphate adsorbents, have limitations including promoting vascular calcification, poor drug compliance due to digestive symptoms, and risk of accumulation in the body, necessitating a more effective compound to inhibit phosphate absorption and improve compliance.
Innovation Solution
A compound represented by a specific general formula, or its pharmacologically acceptable salt, hydrate, or prodrug, which inhibits the active transport of phosphate in the digestive tract, thereby reducing phosphorus absorption and addressing the limitations of existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If phosphate adsorbents (calcium preparations, polymer preparations, metallic salt preparations) are used to treat hyperphosphatemia, then phosphorus absorption is suppressed, but side effects occur including vascular calcification, digestive symptoms, and accumulation risk
Solution Approach 1:
The invention changes the chemical structure parameters of phosphate-binding compounds by introducing specific substituents (R1-R6) at defined positions in the molecular framework, creating a novel compound class with improved pharmacological properties that reduces harmful side effects while maintaining phosphorus binding efficacy
Solution Approach 2:
The patent develops composite molecular structures combining multiple functional groups (carboxylic acid, amide, aromatic rings, and various substituents) in a specific arrangement, creating a composite compound that achieves both phosphorus binding capability and reduced toxicity profile
2Reliability
If polymer preparations are used at high doses to suppress phosphorus absorption, then therapeutic effect is achieved, but drug compliance deteriorates due to digestive symptoms and constipation
Solution Approach 1:
The invention modifies molecular parameters including substituent types (R1-R6), ring structures, and functional group arrangements to create compounds with improved gastrointestinal tolerance, enabling effective phosphorus binding at doses that do not cause severe digestive symptoms
Solution Approach 2:
The patent develops a new generation of phosphate binders that are metabolically transient and do not accumulate in the body, replacing long-term accumulating agents with compounds that are processed and eliminated naturally, reducing chronic toxicity and improving compliance
3Reliability
If metallic salt preparations are used to treat hyperphosphatemia, then phosphorus binding is achieved, but accumulation risk increases in the body
Solution Approach 1:
The patent creates metabolically labile phosphate-binding compounds that are naturally processed and eliminated by the body, replacing persistent metallic salts with organic compounds that do not accumulate, ensuring safe long-term use without body burden
Solution Approach 2:
The invention changes the chemical composition from metallic salts to organic compounds with specific molecular structures (R1-R6 substituents, aromatic rings, carboxylic acid groups) that are compatible with metabolic pathways and do not accumulate in bodily tissues
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively prevents or treats hyperphosphatemia by specifically inhibiting phosphate absorption, improving drug compliance, and minimizing digestive symptoms and accumulation risks, thus enhancing the quality of life for patients with chronic renal failure.
Implementation Method 1
a compound that specifically inhibits the active transport of phosphate can suppress absorption of phosphorus through the digestive tract
Data Source
AI summary
It is an object of the present invention to provide a medicament for preventing or treating hyperphosphatemia. Solution: A compound represented by general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, R1: a methyl group or the like, R2: a hydrogen atom or the like, R3: a hydrogen atom or the like, A: a cyclohexyl ring or the like, X: CH or the like, Y: CH or the like, Z: CH or the like, and n: 2 or the like.]